AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitis

AstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning another FDA submission for the asthma drug, which received an expansion into chronic rhinosinusitis last year.